On 27 April, Regeneron and Sanofi published provisional results from the Phase II section of an ongoing Phase II/III clinical trial assessing Kevzara (sarilumab), in hospitalised patients with severe or critical respiratory illness caused by Covid-19.
The randomised trial compared the drug, administered intravenously at two different doses of 200mg and 400mg, with placebo. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
